Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Investigational RNAi Therapeutic Targeting C5 Is Efficacious in Pre-clinical Models of Myasthenia Gravis.

Kusner LL, Yucius K, Sengupta M, Sprague AG, Desai D, Nguyen T, Charisse K, Kuchimanchi S, Kallanthottathil R, Fitzgerald K, Kaminski HJ, Borodovsky A.

Mol Ther Methods Clin Dev. 2019 May 10;13:484-492. doi: 10.1016/j.omtm.2019.04.009. eCollection 2019 Jun 14.

2.

Publisher Correction: ApoE attenuates unresolvable inflammation by complex formation with activated C1q.

Yin C, Ackermann S, Ma Z, Mohanta SK, Zhang C, Li Y, Nietzsche S, Westermann M, Peng L, Hu D, Bontha SV, Srikakulapu P, Beer M, Megens RTA, Steffens S, Hildner M, Halder LD, Eckstein HH, Pelisek J, Herms J, Roeber S, Arzberger T, Borodovsky A, Habenicht L, Binder CJ, Weber C, Zipfel PF, Skerka C, Habenicht AJR.

Nat Med. 2019 Mar;25(3):529. doi: 10.1038/s41591-019-0378-6.

PMID:
30718908
3.

ApoE attenuates unresolvable inflammation by complex formation with activated C1q.

Yin C, Ackermann S, Ma Z, Mohanta SK, Zhang C, Li Y, Nietzsche S, Westermann M, Peng L, Hu D, Bontha SV, Srikakulapu P, Beer M, Megens RTA, Steffens S, Hildner M, Halder LD, Eckstein HH, Pelisek J, Herms J, Roeber S, Arzberger T, Borodovsky A, Habenicht L, Binder CJ, Weber C, Zipfel PF, Skerka C, Habenicht AJR.

Nat Med. 2019 Mar;25(3):496-506. doi: 10.1038/s41591-018-0336-8. Epub 2019 Jan 28. Erratum in: Nat Med. 2019 Feb 4;:.

4.

An investigational RNAi therapeutic targeting Factor XII (ALN-F12) for the treatment of hereditary angioedema.

Liu J, Qin J, Borodovsky A, Racie T, Castoreno A, Schlegel M, Maier MA, Zimmerman T, Fitzgerald K, Butler J, Akinc A.

RNA. 2019 Feb;25(2):255-263. doi: 10.1261/rna.068916.118. Epub 2018 Nov 21.

PMID:
30463937
5.

Targeting of Liver Mannan-Binding Lectin-Associated Serine Protease-3 with RNA Interference Ameliorates Disease in a Mouse Model of Rheumatoid Arthritis.

Banda NK, Desai D, Scheinman RI, Pihl R, Sekine H, Fujita T, Sharma V, Hansen AG, Garred P, Thiel S, Borodovsky A, Holers VM.

Immunohorizons. 2018 Sep;2(8):274-295. doi: 10.4049/immunohorizons.1800053.

6.

Development of a quantification method for adenosine in tumors by LC-MS/MS with dansyl chloride derivatization.

Goodwin KJ, Gangl E, Sarkar U, Pop-Damkov P, Jones N, Borodovsky A, Woessner R, Fretland AJ.

Anal Biochem. 2019 Mar 1;568:78-88. doi: 10.1016/j.ab.2018.11.004. Epub 2018 Nov 5.

PMID:
30408457
7.

Targeting adenosine A2A receptor antagonism for treatment of cancer.

Congreve M, Brown GA, Borodovsky A, Lamb ML.

Expert Opin Drug Discov. 2018 Nov;13(11):997-1003. doi: 10.1080/17460441.2018.1534825. Epub 2018 Oct 18. Review.

PMID:
30336706
8.

Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide.

Yamashita AS, da Costa Rosa M, Borodovsky A, Festuccia WT, Chan T, Riggins GJ.

Neuro Oncol. 2019 Feb 14;21(2):189-200. doi: 10.1093/neuonc/noy146.

PMID:
30184215
9.

Generation of stable PDX derived cell lines using conditional reprogramming.

Borodovsky A, McQuiston TJ, Stetson D, Ahmed A, Whitston D, Zhang J, Grondine M, Lawson D, Challberg SS, Zinda M, Pollok BA, Dougherty BA, D'Cruz CM.

Mol Cancer. 2017 Dec 6;16(1):177. doi: 10.1186/s12943-017-0745-1.

10.

Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients.

Joshi AD, Botham RC, Schlein LJ, Roth HS, Mangraviti A, Borodovsky A, Tyler B, Joslyn S, Looper JS, Podell M, Fan TM, Hergenrother PJ, Riggins GJ.

Oncotarget. 2017 Jul 7;8(46):80124-80138. doi: 10.18632/oncotarget.19085. eCollection 2017 Oct 6.

11.

A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.

Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, Wijngaard P, Horton JD, Taubel J, Brooks A, Fernando C, Kauffman RS, Kallend D, Vaishnaw A, Simon A.

N Engl J Med. 2017 Jan 5;376(1):41-51. doi: 10.1056/NEJMoa1609243. Epub 2016 Nov 13.

12.

Proliferation and Recruitment Contribute to Myocardial Macrophage Expansion in Chronic Heart Failure.

Sager HB, Hulsmans M, Lavine KJ, Moreira MB, Heidt T, Courties G, Sun Y, Iwamoto Y, Tricot B, Khan OF, Dahlman JE, Borodovsky A, Fitzgerald K, Anderson DG, Weissleder R, Libby P, Swirski FK, Nahrendorf M.

Circ Res. 2016 Sep 16;119(7):853-64. doi: 10.1161/CIRCRESAHA.116.309001. Epub 2016 Jul 21.

13.

RNAi targeting multiple cell adhesion molecules reduces immune cell recruitment and vascular inflammation after myocardial infarction.

Sager HB, Dutta P, Dahlman JE, Hulsmans M, Courties G, Sun Y, Heidt T, Vinegoni C, Borodovsky A, Fitzgerald K, Wojtkiewicz GR, Iwamoto Y, Tricot B, Khan OF, Kauffman KJ, Xing Y, Shaw TE, Libby P, Langer R, Weissleder R, Swirski FK, Anderson DG, Nahrendorf M.

Sci Transl Med. 2016 Jun 8;8(342):342ra80. doi: 10.1126/scitranslmed.aaf1435.

14.

Myocardial Infarction Activates CCR2(+) Hematopoietic Stem and Progenitor Cells.

Dutta P, Sager HB, Stengel KR, Naxerova K, Courties G, Saez B, Silberstein L, Heidt T, Sebas M, Sun Y, Wojtkiewicz G, Feruglio PF, King K, Baker JN, van der Laan AM, Borodovsky A, Fitzgerald K, Hulsmans M, Hoyer F, Iwamoto Y, Vinegoni C, Brown D, Di Carli M, Libby P, Hiebert SW, Scadden DT, Swirski FK, Weissleder R, Nahrendorf M.

Cell Stem Cell. 2015 May 7;16(5):477-87. doi: 10.1016/j.stem.2015.04.008.

15.

Macrophages retain hematopoietic stem cells in the spleen via VCAM-1.

Dutta P, Hoyer FF, Grigoryeva LS, Sager HB, Leuschner F, Courties G, Borodovsky A, Novobrantseva T, Ruda VM, Fitzgerald K, Iwamoto Y, Wojtkiewicz G, Sun Y, Da Silva N, Libby P, Anderson DG, Swirski FK, Weissleder R, Nahrendorf M.

J Exp Med. 2015 Apr 6;212(4):497-512. doi: 10.1084/jem.20141642. Epub 2015 Mar 23.

16.

Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo.

Rajeev KG, Nair JK, Jayaraman M, Charisse K, Taneja N, O'Shea J, Willoughby JL, Yucius K, Nguyen T, Shulga-Morskaya S, Milstein S, Liebow A, Querbes W, Borodovsky A, Fitzgerald K, Maier MA, Manoharan M.

Chembiochem. 2015 Apr 13;16(6):903-8. doi: 10.1002/cbic.201500023. Epub 2015 Mar 18.

PMID:
25786782
17.

A model of a patient-derived IDH1 mutant anaplastic astrocytoma with alternative lengthening of telomeres.

Borodovsky A, Meeker AK, Kirkness EF, Zhao Q, Eberhart CG, Gallia GL, Riggins GJ.

J Neurooncol. 2015 Feb;121(3):479-87. doi: 10.1007/s11060-014-1672-2. Epub 2014 Dec 4.

18.

Repurposing the antihelmintic mebendazole as a hedgehog inhibitor.

Larsen AR, Bai RY, Chung JH, Borodovsky A, Rudin CM, Riggins GJ, Bunz F.

Mol Cancer Ther. 2015 Jan;14(1):3-13. doi: 10.1158/1535-7163.MCT-14-0755-T. Epub 2014 Nov 5.

19.

Silencing of CCR2 in myocarditis.

Leuschner F, Courties G, Dutta P, Mortensen LJ, Gorbatov R, Sena B, Novobrantseva TI, Borodovsky A, Fitzgerald K, Koteliansky V, Iwamoto Y, Bohlender M, Meyer S, Lasitschka F, Meder B, Katus HA, Lin C, Libby P, Swirski FK, Anderson DG, Weissleder R, Nahrendorf M.

Eur Heart J. 2015 Jun 14;36(23):1478-88. doi: 10.1093/eurheartj/ehu225. Epub 2014 Jun 20.

20.

In vivo silencing of the transcription factor IRF5 reprograms the macrophage phenotype and improves infarct healing.

Courties G, Heidt T, Sebas M, Iwamoto Y, Jeon D, Truelove J, Tricot B, Wojtkiewicz G, Dutta P, Sager HB, Borodovsky A, Novobrantseva T, Klebanov B, Fitzgerald K, Anderson DG, Libby P, Swirski FK, Weissleder R, Nahrendorf M.

J Am Coll Cardiol. 2014 Apr 22;63(15):1556-66. doi: 10.1016/j.jacc.2013.11.023. Epub 2013 Dec 18.

21.

Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.

Turcan S, Fabius AW, Borodovsky A, Pedraza A, Brennan C, Huse J, Viale A, Riggins GJ, Chan TA.

Oncotarget. 2013 Oct;4(10):1729-36.

22.

5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.

Borodovsky A, Salmasi V, Turcan S, Fabius AW, Baia GS, Eberhart CG, Weingart JD, Gallia GL, Baylin SB, Chan TA, Riggins GJ.

Oncotarget. 2013 Oct;4(10):1737-47.

23.

Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape.

Gilleron J, Querbes W, Zeigerer A, Borodovsky A, Marsico G, Schubert U, Manygoats K, Seifert S, Andree C, Stöter M, Epstein-Barash H, Zhang L, Koteliansky V, Fitzgerald K, Fava E, Bickle M, Kalaidzidis Y, Akinc A, Maier M, Zerial M.

Nat Biotechnol. 2013 Jul;31(7):638-46. doi: 10.1038/nbt.2612. Epub 2013 Jun 23.

PMID:
23792630
24.

Monocyte-directed RNAi targeting CCR2 improves infarct healing in atherosclerosis-prone mice.

Majmudar MD, Keliher EJ, Heidt T, Leuschner F, Truelove J, Sena BF, Gorbatov R, Iwamoto Y, Dutta P, Wojtkiewicz G, Courties G, Sebas M, Borodovsky A, Fitzgerald K, Nolte MW, Dickneite G, Chen JW, Anderson DG, Swirski FK, Weissleder R, Nahrendorf M.

Circulation. 2013 May 21;127(20):2038-46. doi: 10.1161/CIRCULATIONAHA.112.000116. Epub 2013 Apr 24.

25.

Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells.

Novobrantseva TI, Borodovsky A, Wong J, Klebanov B, Zafari M, Yucius K, Querbes W, Ge P, Ruda VM, Milstein S, Speciner L, Duncan R, Barros S, Basha G, Cullis P, Akinc A, Donahoe JS, Narayanannair Jayaprakash K, Jayaraman M, Bogorad RL, Love K, Whitehead K, Levins C, Manoharan M, Swirski FK, Weissleder R, Langer R, Anderson DG, de Fougerolles A, Nahrendorf M, Koteliansky V.

Mol Ther Nucleic Acids. 2012 Jan 24;1:e4. doi: 10.1038/mtna.2011.3.

26.

Polymeric nanoparticle PET/MR imaging allows macrophage detection in atherosclerotic plaques.

Majmudar MD, Yoo J, Keliher EJ, Truelove JJ, Iwamoto Y, Sena B, Dutta P, Borodovsky A, Fitzgerald K, Di Carli MF, Libby P, Anderson DG, Swirski FK, Weissleder R, Nahrendorf M.

Circ Res. 2013 Mar 1;112(5):755-61. doi: 10.1161/CIRCRESAHA.111.300576. Epub 2013 Jan 8.

27.

Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists.

Kim J, Aftab BT, Tang JY, Kim D, Lee AH, Rezaee M, Kim J, Chen B, King EM, Borodovsky A, Riggins GJ, Epstein EH Jr, Beachy PA, Rudin CM.

Cancer Cell. 2013 Jan 14;23(1):23-34. doi: 10.1016/j.ccr.2012.11.017. Epub 2013 Jan 3.

28.

Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery.

Lee H, Lytton-Jean AK, Chen Y, Love KT, Park AI, Karagiannis ED, Sehgal A, Querbes W, Zurenko CS, Jayaraman M, Peng CG, Charisse K, Borodovsky A, Manoharan M, Donahoe JS, Truelove J, Nahrendorf M, Langer R, Anderson DG.

Nat Nanotechnol. 2012 Jun 3;7(6):389-93. doi: 10.1038/nnano.2012.73.

29.

Use of anti-cancer drugs, mitocans, to enhance the immune responses against tumors.

Hahn T, Polanczyk MJ, Borodovsky A, Ramanathapuram LV, Akporiaye ET, Ralph SJ.

Curr Pharm Biotechnol. 2013;14(3):357-76. Review.

30.

Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2.

Borodovsky A, Seltzer MJ, Riggins GJ.

Curr Opin Oncol. 2012 Jan;24(1):83-9. doi: 10.1097/CCO.0b013e32834d816a. Review.

31.

TWEAK/Fn14 pathway: a nonredundant role in intestinal damage in mice through a TWEAK/intestinal epithelial cell axis.

Dohi T, Borodovsky A, Wu P, Shearstone JR, Kawashima R, Runkel L, Rajman L, Dong X, Scott ML, Michaelson JS, Jakubowski A, Burkly LC.

Gastroenterology. 2009 Mar;136(3):912-23. doi: 10.1053/j.gastro.2008.11.017. Epub 2008 Nov 8.

PMID:
19109961
32.

A combinatorial library of lipid-like materials for delivery of RNAi therapeutics.

Akinc A, Zumbuehl A, Goldberg M, Leshchiner ES, Busini V, Hossain N, Bacallado SA, Nguyen DN, Fuller J, Alvarez R, Borodovsky A, Borland T, Constien R, de Fougerolles A, Dorkin JR, Narayanannair Jayaprakash K, Jayaraman M, John M, Koteliansky V, Manoharan M, Nechev L, Qin J, Racie T, Raitcheva D, Rajeev KG, Sah DW, Soutschek J, Toudjarska I, Vornlocher HP, Zimmermann TS, Langer R, Anderson DG.

Nat Biotechnol. 2008 May;26(5):561-9. doi: 10.1038/nbt1402. Epub 2008 Apr 27.

33.

Applications for chemical probes of proteolytic activity.

Bogyo M, Baruch A, Jeffery DA, Greenbaum D, Borodovsky A, Ovaa H, Kessler B.

Curr Protoc Protein Sci. 2004 Sep;Chapter 21:Unit 21.17. doi: 10.1002/0471140864.ps2117s36.

PMID:
18429259
34.

TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease.

Pappu BP, Borodovsky A, Zheng TS, Yang X, Wu P, Dong X, Weng S, Browning B, Scott ML, Ma L, Su L, Tian Q, Schneider P, Flavell RA, Dong C, Burkly LC.

J Exp Med. 2008 May 12;205(5):1049-62. doi: 10.1084/jem.20071364. Epub 2008 Apr 14.

35.

Delivering silence: advancements in developing siRNA therapeutics.

Novobrantseva TI, Akinc A, Borodovsky A, de Fougerolles A.

Curr Opin Drug Discov Devel. 2008 Mar;11(2):217-24. Review.

PMID:
18283609
36.

Small-molecule inhibitors and probes for ubiquitin- and ubiquitin-like-specific proteases.

Borodovsky A, Ovaa H, Meester WJ, Venanzi ES, Bogyo MS, Hekking BG, Ploegh HL, Kessler BM, Overkleeft HS.

Chembiochem. 2005 Feb;6(2):287-91. No abstract available.

PMID:
15651044
37.

Chemistry-based functional proteomics: mechanism-based activity-profiling tools for ubiquitin and ubiquitin-like specific proteases.

Hemelaar J, Galardy PJ, Borodovsky A, Kessler BM, Ploegh HL, Ovaa H.

J Proteome Res. 2004 Mar-Apr;3(2):268-76. Review.

PMID:
15113103
38.

Specific and covalent targeting of conjugating and deconjugating enzymes of ubiquitin-like proteins.

Hemelaar J, Borodovsky A, Kessler BM, Reverter D, Cook J, Kolli N, Gan-Erdene T, Wilkinson KD, Gill G, Lima CD, Ploegh HL, Ovaa H.

Mol Cell Biol. 2004 Jan;24(1):84-95.

39.

Pathways accessory to proteasomal proteolysis are less efficient in major histocompatibility complex class I antigen production.

Kessler B, Hong X, Petrovic J, Borodovsky A, Dantuma NP, Bogyo M, Overkleeft HS, Ploegh H, Glas R.

J Biol Chem. 2003 Mar 21;278(12):10013-21. Epub 2002 Dec 16.

40.

The ubiquitin-proteasome pathway in thymocyte apoptosis: caspase-dependent processing of the deubiquitinating enzyme USP7 (HAUSP).

Vugmeyster Y, Borodovsky A, Maurice MM, Maehr R, Furman MH, Ploegh HL.

Mol Immunol. 2002 Nov;39(7-8):431-41.

PMID:
12413694
41.

Multiple associated proteins regulate proteasome structure and function.

Leggett DS, Hanna J, Borodovsky A, Crosas B, Schmidt M, Baker RT, Walz T, Ploegh H, Finley D.

Mol Cell. 2002 Sep;10(3):495-507.

42.

Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme family.

Borodovsky A, Ovaa H, Kolli N, Gan-Erdene T, Wilkinson KD, Ploegh HL, Kessler BM.

Chem Biol. 2002 Oct;9(10):1149-59.

43.

A novel active site-directed probe specific for deubiquitylating enzymes reveals proteasome association of USP14.

Borodovsky A, Kessler BM, Casagrande R, Overkleeft HS, Wilkinson KD, Ploegh HL.

EMBO J. 2001 Sep 17;20(18):5187-96.

44.

Integration of the ubiquitin-proteasome pathway with a cytosolic oligopeptidase activity.

Wang EW, Kessler BM, Borodovsky A, Cravatt BF, Bogyo M, Ploegh HL, Glas R.

Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):9990-5.

45.

BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression.

Jensen DE, Proctor M, Marquis ST, Gardner HP, Ha SI, Chodosh LA, Ishov AM, Tommerup N, Vissing H, Sekido Y, Minna J, Borodovsky A, Schultz DC, Wilkinson KD, Maul GG, Barlev N, Berger SL, Prendergast GC, Rauscher FJ 3rd.

Oncogene. 1998 Mar 5;16(9):1097-112.

PMID:
9528852

Supplemental Content

Loading ...
Support Center